RU2390353C2 - Высококонцентрированные жидкие композиции анти-egfr антител - Google Patents

Высококонцентрированные жидкие композиции анти-egfr антител Download PDF

Info

Publication number
RU2390353C2
RU2390353C2 RU2006132466/13A RU2006132466A RU2390353C2 RU 2390353 C2 RU2390353 C2 RU 2390353C2 RU 2006132466/13 A RU2006132466/13 A RU 2006132466/13A RU 2006132466 A RU2006132466 A RU 2006132466A RU 2390353 C2 RU2390353 C2 RU 2390353C2
Authority
RU
Russia
Prior art keywords
mab
highly concentrated
liquid composition
compositions
protein
Prior art date
Application number
RU2006132466/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2006132466A (ru
Inventor
Зузанне МАТЕУС (DE)
Зузанне МАТЕУС
Ханнс-Кристиан МАЛЕР (DE)
Ханнс-Кристиан Малер
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of RU2006132466A publication Critical patent/RU2006132466A/ru
Application granted granted Critical
Publication of RU2390353C2 publication Critical patent/RU2390353C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
RU2006132466/13A 2004-02-12 2005-01-27 Высококонцентрированные жидкие композиции анти-egfr антител RU2390353C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54354904P 2004-02-12 2004-02-12
US60/543,549 2004-02-12

Publications (2)

Publication Number Publication Date
RU2006132466A RU2006132466A (ru) 2008-03-20
RU2390353C2 true RU2390353C2 (ru) 2010-05-27

Family

ID=34860438

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006132466/13A RU2390353C2 (ru) 2004-02-12 2005-01-27 Высококонцентрированные жидкие композиции анти-egfr антител

Country Status (13)

Country Link
US (2) US20070172475A1 (fr)
EP (1) EP1713502A1 (fr)
JP (1) JP2007522157A (fr)
KR (2) KR20120089307A (fr)
CN (1) CN1953768B (fr)
AR (1) AR047611A1 (fr)
AU (1) AU2005211890B2 (fr)
BR (1) BRPI0507608A (fr)
CA (1) CA2555791A1 (fr)
HK (1) HK1103281A1 (fr)
RU (1) RU2390353C2 (fr)
WO (1) WO2005077414A1 (fr)
ZA (1) ZA200607600B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10994011B2 (en) 2015-12-18 2021-05-04 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human TSLP receptor antibody
RU2767044C1 (ru) * 2021-07-19 2022-03-16 Акционерное общество "РАДИОАВИОНИКА" Бортовой ретранслятор комплекса обеспечения радиосвязи разведывательно-ударной системы с беспилотными летательными аппаратами
RU2794148C2 (ru) * 2015-12-18 2023-04-12 Апстрим Байо, Инк. Фармацевтическая композиция, содержащая антитело к рецептору tslp человека

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
EP2042194A3 (fr) * 1999-05-14 2009-04-22 Imclone Systems, Inc. Traitement des tumeurs humaines réfractaires avec des antagonistes de récepteur de facteur de croissance épidermique
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1622941A2 (fr) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Procede de production d'un anticorps contre le recepteur du facteur de croissance epidermique
CN103007279B (zh) * 2004-03-19 2017-01-11 英克隆有限责任公司 人抗表皮生长因子受体抗体
AU2005244842B2 (en) * 2004-05-12 2010-09-23 Baxter Healthcare S.A. Nucleic acid microspheres, production and delivery thereof
CN103393601A (zh) 2004-05-12 2013-11-20 巴克斯特国际公司 含有蛋白并在高浓度蛋白下显示可注射性的微球体
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
JP2007537288A (ja) * 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US7919264B2 (en) 2005-11-01 2011-04-05 Abbott Biotechnology Ltd. Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers
EA015173B1 (ru) * 2006-01-04 2011-06-30 Мерк Патент Гмбх Комбинированная терапия с использованием антител к egfr и her2
CN101500616A (zh) 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
KR20090060453A (ko) * 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
KR20080051236A (ko) 2006-12-05 2008-06-11 삼성전자주식회사 엘이디 패키지 및 그 엘이디 패키지를 포함하는 광원유닛및 백라이트 유닛
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
KR20100014674A (ko) * 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
JP5744513B2 (ja) * 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
WO2008135380A1 (fr) * 2007-05-02 2008-11-13 F. Hoffmann-La Roche Ag Procédé de stabilisation d'une protéine
EP2679996A1 (fr) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarqueurs prédictifs de la réactivité aux inhibiteurs TNF-alfa dans des troubles auto-immuns
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
RU2497545C2 (ru) * 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
BRPI0921320A2 (pt) * 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
JP2012511531A (ja) * 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
AU2010291927A1 (en) * 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
CN103282042B (zh) 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
CN102552875B (zh) * 2010-12-09 2015-05-20 上海国健生物技术研究院 一种双功能vegf受体融合蛋白制剂
CN102153649B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l1-h3及其编码基因与应用
PL2672994T3 (pl) 2011-02-11 2018-11-30 Merck Patent Gmbh Przeciwciało przeciwko integrynie alfa-v do leczenia raka prostaty
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9822170B2 (en) * 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014052713A2 (fr) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Protéines de liaison à her2 et vegf-a à stabilité améliorée
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
WO2015051293A2 (fr) 2013-10-04 2015-04-09 Abbvie, Inc. Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2017024152A1 (fr) * 2015-08-05 2017-02-09 Dow Global Technologies Llc Compositions et procédés d'élimination des odeurs
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
WO2018204374A1 (fr) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN108250297B (zh) * 2018-01-23 2021-07-23 上海生物制品研究所有限责任公司 抗egfr抗体、其制法及其应用
CN113015747A (zh) 2018-10-19 2021-06-22 默克专利股份公司 用于治疗结肠直肠癌的阿比妥单抗
CN115300623B (zh) * 2021-05-08 2024-06-21 盛禾(中国)生物制药有限公司 抗egfr融合蛋白或其抗原结合片段的组合物及其用途
WO2024010886A2 (fr) * 2022-07-07 2024-01-11 Nanostar Pharmaceuticals Ltd. Formulation de médicament à vésicules multilamellaires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
US20060182740A1 (en) * 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
CA2450289A1 (fr) * 2003-03-20 2005-05-19 Imclone Systems Incorporated Methode de production d'un anticorps ciblant le recepteur du facteur de croissance epidermique

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10994011B2 (en) 2015-12-18 2021-05-04 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human TSLP receptor antibody
RU2794148C2 (ru) * 2015-12-18 2023-04-12 Апстрим Байо, Инк. Фармацевтическая композиция, содержащая антитело к рецептору tslp человека
US11712472B2 (en) 2015-12-18 2023-08-01 Upstream Bio, Inc. Pharmaceutical composition comprising anti-human TSLP receptor antibody
RU2767044C1 (ru) * 2021-07-19 2022-03-16 Акционерное общество "РАДИОАВИОНИКА" Бортовой ретранслятор комплекса обеспечения радиосвязи разведывательно-ударной системы с беспилотными летательными аппаратами

Also Published As

Publication number Publication date
CA2555791A1 (fr) 2005-08-25
HK1103281A1 (en) 2007-12-14
EP1713502A1 (fr) 2006-10-25
BRPI0507608A (pt) 2007-07-03
KR20120089307A (ko) 2012-08-09
AU2005211890B2 (en) 2011-07-28
KR20060121956A (ko) 2006-11-29
CN1953768A (zh) 2007-04-25
RU2006132466A (ru) 2008-03-20
US20120076784A1 (en) 2012-03-29
AR047611A1 (es) 2006-01-25
WO2005077414A1 (fr) 2005-08-25
ZA200607600B (en) 2008-04-30
US20070172475A1 (en) 2007-07-26
JP2007522157A (ja) 2007-08-09
KR101342735B1 (ko) 2013-12-19
AU2005211890A1 (en) 2005-08-25
CN1953768B (zh) 2010-10-13

Similar Documents

Publication Publication Date Title
RU2390353C2 (ru) Высококонцентрированные жидкие композиции анти-egfr антител
RU2397755C2 (ru) Твердые формы анти-egfr антител
US10463668B2 (en) Methods of treating and preventing graft versus host disease
KR20200011957A (ko) 암 치료를 위한 조합 요법
US12065494B2 (en) Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
MXPA06009001A (en) Highly concentrated liquid formulations of anti-egfr antibodies
JP2008519757A (ja) 抗ｅｇｆｒ抗体の固形物
WO2023174278A1 (fr) Composition pharmaceutique d'anticorps anti-tim-3 et d'agent d'hypométhylation
CN114867468A (zh) 尼妥珠单抗的稳定和高浓度制剂
CN118681010A (zh) 用于治疗肺癌的药物组合

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170128